Tysabri Pregnancy Category

Although
 Tysabri® (natalizumab) has not been adequately studied in pregnant women, this drug caused miscarriages and blood cell problems in the offspring when it was given to pregnant animals. As a result of these complications, the U.S. Food and Drug Administration (FDA) classified Tysabri as a pregnancy Category C drug.
 
A pregnancy Category C medicine, such as Tysabri, should only be given to a pregnant woman if the healthcare provider believes that the benefits to the woman outweigh any possible risks to her unborn child.
 
(For more details on the risks of receiving this drug during pregnancy, click Tysabri and Pregnancy.)
Written by/reviewed by: Susan Lakey, PharmD, MPH, BCPP
Last reviewed by: Kristi Monson, PharmD
 
Referring Pages Articles